PL2205273T3 - Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego - Google Patents

Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego

Info

Publication number
PL2205273T3
PL2205273T3 PL08845159T PL08845159T PL2205273T3 PL 2205273 T3 PL2205273 T3 PL 2205273T3 PL 08845159 T PL08845159 T PL 08845159T PL 08845159 T PL08845159 T PL 08845159T PL 2205273 T3 PL2205273 T3 PL 2205273T3
Authority
PL
Poland
Prior art keywords
treatment
multiple sclerosis
modified cells
cells
modified
Prior art date
Application number
PL08845159T
Other languages
English (en)
Inventor
Roland Martin
Andreas Lutterotti
Stephen Miller
Original Assignee
Universität Zürich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich filed Critical Universität Zürich
Publication of PL2205273T3 publication Critical patent/PL2205273T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL08845159T 2007-10-31 2008-10-31 Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego PL2205273T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07075952A EP2057998A1 (en) 2007-10-31 2007-10-31 Use of modified cells for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
PL2205273T3 true PL2205273T3 (pl) 2017-09-29

Family

ID=39167402

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08845159T PL2205273T3 (pl) 2007-10-31 2008-10-31 Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego

Country Status (8)

Country Link
US (1) US8673293B2 (pl)
EP (2) EP2057998A1 (pl)
DK (1) DK2205273T3 (pl)
ES (1) ES2601329T3 (pl)
HU (1) HUE030745T2 (pl)
PL (1) PL2205273T3 (pl)
PT (1) PT2205273T (pl)
WO (1) WO2009056332A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
TW201039843A (en) * 2009-01-20 2010-11-16 Myelin Repair Foundation Inc Compositions and methods for induced tolerance
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011325966B2 (en) 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
FI3467509T3 (fi) * 2011-05-04 2026-02-11 Cellular Tech Ltd Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa
PT2768942T (pt) 2011-10-17 2020-01-21 Massachusetts Inst Technology Entrega intracelular
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
EP3494966B1 (en) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immune-modifying particles for the treatment of inflammation
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
KR102243597B1 (ko) 2013-08-16 2021-04-26 메사추세츠 인스티튜트 오브 테크놀로지 세포로의 선택적 물질 전달
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
MA39819A (fr) 2014-04-01 2017-02-08 Rubius Therapeutics Inc Méthodes et compositions d'immunomodulation
KR20170074235A (ko) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
CN107002089B (zh) 2014-11-14 2021-09-07 麻省理工学院 化合物和组合物向细胞中的破坏和场实现的递送
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
AU2016289530B2 (en) 2015-07-09 2021-05-06 Massachusetts Institute Of Technology Delivery of materials to anucleate cells
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
CA3023092A1 (en) 2016-05-03 2017-11-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
CN119097696A (zh) 2017-03-29 2024-12-10 Neogap治疗学公司 多发性硬化症相关的自身抗原及其在疗法和诊断中的用途
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
EP3586866A1 (en) 2018-06-28 2020-01-01 Universität Zürich Immunodominant proteins and fragments in multiple sclerosis
KR20230171998A (ko) 2021-04-16 2023-12-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 면역학적 관용의 유지를 추적하는 방법
EP4370927A1 (en) 2021-07-16 2024-05-22 Universität Zürich Method for stratification and treatment of multiple sclerosis
EP4119948A1 (en) 2021-07-16 2023-01-18 Universität Zürich Method for stratification and treatment of multiple sclerosis
EP4611796A1 (en) 2022-11-01 2025-09-10 Universität Zürich Novel mbp peptides and their use in the treatment of multiple sclerosis
EP4553083A1 (en) 2023-11-10 2025-05-14 Cellerys AG Peptides and their use for the treatment and/or prevention of multiple sclerosis
AR134272A1 (es) 2023-11-10 2025-12-17 Univ Zuerich Peptidos y su uso para el tratamiento y/o la prevencion de esclerosis multiple

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
US20110033426A1 (en) 2011-02-10
US8673293B2 (en) 2014-03-18
DK2205273T3 (en) 2016-12-19
EP2205273A1 (en) 2010-07-14
EP2057998A1 (en) 2009-05-13
EP2205273B1 (en) 2016-09-28
PT2205273T (pt) 2016-12-29
ES2601329T3 (es) 2017-02-14
WO2009056332A1 (en) 2009-05-07
HUE030745T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
PL2205273T3 (pl) Zastosowanie zmodyfikowanych komórek w leczeniu stwardnienia rozsianego
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0908173D0 (en) Process for facilitating the management of care
PL2954932T3 (pl) Zastosowanie terapeutyczne diaminofenotiazyn
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
GB0722680D0 (en) Therapeutic compounds and their use
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
GB0909297D0 (en) Composition for the treatment of skin conditions
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB0822486D0 (en) Compounds for use in the treatment of pain
GB0710981D0 (en) New Therapeutic use
GB0708452D0 (en) Treatment of nuclear studge
IL206189A (en) Compounds for use in cancer treatment
PL2323625T3 (pl) Nowa kompozycja do leczenia pigmentacji wybroczynowych
GB0723100D0 (en) Treatment of HFnEF
GB2451349B (en) Epicondylitis treatment
GB0808690D0 (en) Therapeutic use
IL184620A0 (en) Composition for the treatment of inflammation
GB0705517D0 (en) Therapeutic compounds and their use
GB0602857D0 (en) The treatment of sialorrhoea
GB0609792D0 (en) The treatment of multiple sclerosis
GB0602858D0 (en) The treatment of sialorrhoea
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0809319D0 (en) The treatment of puritus